Technology Profile Clause Samples

Technology Profile. The federally supported ([***], [***]) technologies resulted in the filing of a U.S. Patent Application in February of 1994, covering a method and compound for the treatment of Hepatitis B Virus (HBV). The inhibitory effects of the L-analogs of nucleotides represent a new strategy in the development of potential drugs against viruses like HBV, EBV, and HIV. Lack of toxicity of these compounds in the human systems in comparison to their D-counterparts and efficient inhibition of viral processes makes it a novel strategy to combat viral diseases. L-FMAU falls into this category and could prove to be a very active anti viral agent against HBV and EBV.